TC-A 2317 hydrochloride
Cat. No. 4066
Chemical Name: 2-[(5-Hydroxy-1,5-dimethylhexyl)amino]-4-methyl-6-[(5-methyl-1H-pyrazol-3-yl)amino]-3-pyridinecarbonitrile hydrochloride
Biological ActivityPotent Aurora kinase A inhibitor (Ki = 1.2 nM compared to 101 nM for inhibition of Aurora kinase B). Selective over 60 other kinases (IC50 values > 1000 nM). Exhibits good cell permeability and antitumor activity.
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
Ando et al (2010) 3-Cyano-6-(-5-methyl-3-pyrazoloamino)pyridines: Selective Aurora A kinase inhibitors. Bioorg.Med.Chem.Lett. 20 4709. PMID: 20573509.
If you know of a relevant citation for this product please let us know.
Keywords: TC-A 2317 hydrochloride, supplier, inhibits, aurora, kinase, a, inhibitor, antitumor, Aurora, A
Find multiple products by catalog number
New Products in this Area
Cyclin-dependent kinase inhibitorGSK2578215A
Potent, selective LRRK2 inhibitor; brain penetrantAmlexanox
Inhibitor of TBK1 and IKKε; antiallergic agentPF 05212384
Potent and selective dual PI 3-kinase/mTOR inhibitorPF 03814735
Aurora kinase A and B inhibitorPF 04691502
Dual PI 3-K/mTOR inhibitorTNP
Inhibitor of IP6K; also inhibits IP3KACHP
Selective IKKα and IKKβ inhibitorPD 0332991 isethionate
Potent, selective Cdk4/6 inhibitor; brain penetrantCZC 24832
Selective inhibitor of PI 3-Kinase γLY 333531 hydrochloride
Protein kinase C inhibitor; selective for β isozymesPF 06465469
Potent inhibitor of interleukin-2 inducible T cell kinase (ITK). Also inhibits BTK10Z-Hymenialdisine
Pan kinase inhibitor; potently inhibits MEK-1CP 690550 citrate
Potent JAK inhibitorWYE 687 dihydrochloride
Potent and selective mTOR inhibitorN,N-Dimethylsphingosine
Sphingosine kinase inhibitorPEP 005
Protein kinase C activatorCZC 54252 hydrochloride
Potent LRRK2 inhibitor; neuroprotectiveBisindolylmaleimide II
Potent PKC inhibitor and nicotinic receptor antagonistCID 2011756
Pan protein kinase D (PKD) inhibitor; cell permeable
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.